The Supreme Court rules that a group lacked legal standing in a case challenging the FDA’s approval of an abortion medication.
The Food and medicine Administration’s (FDA) regulatory clearance procedure for the abortion medicine mifepristone was challenged, and the Supreme Court rejected the appeal on Thursday. This is the latest abortion case since the historic 2022 ruling that reversed Roe v. Wade.
Challengers to the FDA lacked standing to sue the government, the Supreme Court said unanimously, in a victory for the Biden administration and proponents of abortion rights.
“A plaintiff does not establish standing to suit under Article III of the Constitution just because they wish to restrict the availability of a medicine for others. The majority opinion’s author, Justice Brett Kavanaugh, added, “Nor do the plaintiffs’ other standing theories suffice.”
“The plaintiffs have sincere legal, moral, ideological, and policy objections to elective abortion and to FDA’s relaxed regulation of mifepristone,” he stated. “But under Article III of the Constitution, those kinds of objections alone do not establish a justiciable case or controversy in federal court.” Remanded in accordance with the Court’s decision, the matter was sent back to the Fifth Circuit.
